Presentation and Status in Health Basket
| Presentation | Basket | Yarpa | Pharmasoft |
|---|---|---|---|
|
Film Coated Tablets 30 X 10 mg |
|
2764 | 19432 |
|
Film Coated Tablets 30 X 20 mg |
|
2765 | 19433 |
|
Film Coated Tablets 30 X 40 mg |
|
27410 | 19437 |
|
Film Coated Tablets 30 X 80 mg |
|
4394 | 19450 |
Related information
Dosage
See prescribing information for full details.
Indications
In patients with coronary heart disease and hypercholesterolemia to: reduce the risk of total mortality by reducing coronary death; reduce the risk of non-fatal myocardial infarcation; reduce the risk for undergoing myocardial revascularization procedures; reduce the risk of stroke and transient ischemic attacks (TIA)., hyperlipidemia. Also indicated as an adjunct to diet to reduce elevated TOTAL-C, LDL-C, Apo B and TG, and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson types 11a and 11b) by lowering the LDL-C/HDL-C and the total C/HDL-C ratios. In homozygous familial hypercholesterolemia as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol, LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hypertriglyceridemia (Fredrickson type IV hyperlipidemia): for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipdemia).
Contra-Indications
Hypersensitivity to component, active liver disease, unexplained persisting elevated serum transaminases, pregnancy, lactation, concomitant therapy with tetralol class calcium channel blocker. Not recommended in patients under 20 years.
Special Precautions
See prescribing information for full details.
Side Effects
Generally well tolerated. Abdominal pain, constipation, flatulence, nausea, dyspepsia, headache, diarrhea, fatigue, rash, insomnia and hepatitis.
